• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Proteome science >A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression
【24h】

A preliminary quantitative proteomic analysis of glioblastoma pseudoprogression

机译：胶质母细胞瘤假进展的初步定量蛋白质组学分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Backgrounds Pseudoprogression disease (PsPD) is commonly observed during glioblastoma (GBM) follow-up after adjuvant therapy. Because it is difficult to differentiate PsPD from true early progression of GBM, we have used a quantitative proteomics strategy to identify molecular signatures and develop predictive markers of PsPD. Results An initial screening of three PsPD and three GBM patients was performed, and from which 530 proteins with significant fold changes were identified. By conducting biological functional analysis of these proteins, we found evidence that the protein synthesis network and the cellular growth and proliferation network were most significantly affected. Moreover, six of the proteins (HNRNPK, ELAVL1, CDH2, FBLN1, CALU and FGB) involved in the two networks were validated (n?=?18) in the same six samples and in twelve additional samples using immunohistochemistry methods and the western blot analysis. The receiver operating characteristic (ROC) curve analysis in distinguishing PsPD patients from GBM patients yielded an area under curve (AUC) value of 0.90 (95% confidence interval (CI), 0.662-0.9880) for CDH2 and.0.92 (95% CI, 0.696-0.995) for CDH2 combined with ELAVL1. Conclusions The results of the present study both revealed the biological signatures of PsPD from a proteomics perspective and indicated that CDH2 alone or combined with ELAVL1 could be potential biomarkers with high accuracy in the diagnosis of PsPD.
机译：背景假性进展疾病（PsPD）通常在辅助治疗后的胶质母细胞瘤（GBM）随访期间观察到。由于很难将PsPD与GBM的真正早期进展区分开，因此我们使用了定量蛋白质组学策略来鉴定分子标记并开发PsPD的预测标记。结果对3例PsPD和3例GBM患者进行了初步筛查，从中鉴定出530种具有明显倍数变化的蛋白质。通过对这些蛋白质进行生物学功能分析，我们发现证据表明蛋白质合成网络以及细胞生长和增殖网络受到的影响最大。此外，使用免疫组织化学方法和western blot在相同的六个样品和另外十二个样品中验证了涉及两个网络的六个蛋白（HNRNPK，ELAVL1，CDH2，FBLN1，CALU和FGB）（n≥18）。分析。区分PsPD患者和GBM患者的受试者工作特征（ROC）曲线分析得出CDH2为0.90（95％置信区间（CI），0.662-0.9880）的曲线下面积（AUC）值为0.92（95％CI为0.92， 0.696-0.995）用于CDH2与ELAVL1的组合。结论本研究的结果从蛋白质组学角度揭示了PsPD的生物学特征，并表明CDH2单独或与ELAVL1结合可以成为潜在的生物标志物，对PsPD的诊断具有较高的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号